Lurbinectedin (Zepzelca®) is considered medically necessary and, therefore, covered as a single agent for the subsequent treatment of adult individuals with advanced or metastatic small cell lung cancer (SCLC) when all of the following criteria are are met:
REQUIRED DOCUMENTATION The individual's medical record must reflect the medical necessity for the care provided. These medical records may include, but are not limited to: records from the professional provider's office, hospital, nursing home, home health agencies, therapies, and test reports. The Company may conduct reviews and audits of services to our members, regardless of the participation status of the provider. All documentation is to be available to the Company upon request. Failure to produce the requested information may result in a denial for the service.
This version of the policy will become effective 05/24/2021.
This policy has been updated to communicate the Company's coverage position for lurbinectedin (Zepzelca), in alignment with US Food and Drug Administration (FDA) and National Comprehensive Cancer Network (NCCN).
The following NOC codes have been removed from this policy and are replaced by the following HCPCS code:
REMOVED:
C9399 Unclassified drugs or biologicals J3490 Unclassified drugsREPLACED WITH: J9223 Injection, lurbinectedin, 0.1 mg